thalidomide has been researched along with plitidepsin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Caballero, D; Coiffier, B; d'Amore, F; Dearden, C; Federico, M; Gomes da Silva, M; Jäger, U; Morschhauser, F; Pettengell, R; Tilly, H; Trümper, L; Weidmann, E; Zinzani, PL; Zucca, E | 1 |
| Alfaro, V; Banh, RH; Cannell, P; Carella, AM; D'Rozario, JM; Dimopoulos, MA; Extremera, S; Greil, R; Hájek, R; Huang, SY; Kahatt, C; Ludwig, H; Martínez, S; Mateos, MV; Meuleman, N; Min, CK; Oakervee, HE; Ocio, EM; Sonneveld, P; Spicka, I; Symeonidis, A | 1 |
1 review(s) available for thalidomide and plitidepsin
| Article | Year |
|---|---|
Therapeutic options in relapsed or refractory peripheral T-cell lymphoma.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Cyclophosphamide; Depsipeptides; Diphtheria Toxin; Doxorubicin; Folic Acid Antagonists; Histone Deacetylase Inhibitors; Humans; Immunoconjugates; Interleukin-2; Lenalidomide; Lymphoma, T-Cell, Peripheral; Neoplasm Recurrence, Local; Peptides, Cyclic; Prednisolone; Recombinant Fusion Proteins; Stem Cell Transplantation; Thalidomide; Topoisomerase Inhibitors; Vincristine | 2014 |
1 trial(s) available for thalidomide and plitidepsin
| Article | Year |
|---|---|
Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Depsipeptides; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Peptides, Cyclic; Survival Rate; Thalidomide | 2019 |